Cytomegalovirus-specific hyperimmune globulin clinical trials
Also written Cytogam and Cytotect.
How each study uses cytomegalovirus-specific hyperimmune globulin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the cytomegalovirus-specific hyperimmune globulin studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 17 Apr 1990 · Cytogam · BLA 103189 (FDA, Purple Book)
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2025 (2)
| Year | Studies |
|---|---|
| 2001 | 1 |
| 2009 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2021 | 1 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 0 · Other 7
University Hospital, Bordeaux (1) · The George Washington University Biostatistics Center (1) · Medical University of South Carolina (1) · Fondazione IRCCS Policlinico San Matteo di Pavia (1) · The Cleveland Clinic (1) · Fernanda P Silveira, MD, MS (1) · University of Minnesota (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test cytomegalovirus-specific hyperimmune globulin.
- Aug 2027CMVIG Prophylaxis in Belatacept Conversion Kidney Transplant RecipientsPhase 1/2 · University of Minnesota
Studies
Open first, then newest update. How each study uses cytomegalovirus-specific hyperimmune globulin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- CMVIG Prophylaxis in Belatacept Conversion Kidney Transplant RecipientsRecruitingPhase 1/2University of MinnesotaNCT07096453Written as Cytogam
- CytoGam for CMV Infection or Disease in Solid Organ Transplant RecipientsEnrolling by invitationPhase 4Fernanda P Silveira, MD, MSNCT07009548Written as Cytogam
- Association of T Gamma Delta-CD16+ Cells and Anti-CMV Immunoglobulins in the Prevention of CMV InfectionCompletedPhase 2University Hospital, BordeauxNCT04934527Written as Cytotect
- A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV)CompletedPhase 3The George Washington University Biostatistics CenterNCT01376778Written as CMV hyperimmune globulin
- Cytogam Administration in Abdominal Organ Transplant Recipients at High Risk for Cytomegalovirus InfectionCompletedPhase 4Medical University of South CarolinaNCT01509404Written as CMV hyperimmune globulin
- Efficacy Study of Human Cytomegalovirus (HCMV) Hyperimmune Globulin to Prevent Congenital HCMV InfectionCompletedPhase 2/3Fondazione IRCCS Policlinico San Matteo di PaviaNCT00881517Written as HCMV-specific hyperimmune globulin (Cytotect®)
- Cytomegalovirus Hyperimmune Globulin (CMV-Ig) Replacement in Hypogammaglobulinemic Lung Transplant RecipientsCompletedPhase 2/3The Cleveland ClinicNCT00137748Written as CMV-Ig
Given beside what is tested · 1 — cytomegalovirus-specific hyperimmune globulin is usual care or a partner of the new treatment
Codes
What other systems call cytomegalovirus-specific hyperimmune globulin · ClinicalTrials.gg INT003219
- MeSH (NLM) C045781cytomegalovirus-specific hyperimmune globulinOne source NLM
- UNII (FDA) 129L90A25NHUMAN CYTOMEGALOVIRUS IMMUNE GLOBULINConfirmed FDA, NLM
- RxNorm 1997443One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C045781 | cytomegalovirus-specific hyperimmune globulin | One source NLM |
| UNII (FDA) | 129L90A25N | HUMAN CYTOMEGALOVIRUS IMMUNE GLOBULIN | Confirmed FDA, NLM |
| RxNorm | 1997443 | — | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.